Guard Therapeutics: Positive Data – MAD Study
Redeye raises its base and bear case for Guard Therapeutics to 3,3 SEK/share and 1,3 SEK/share respectively. Today, Guard Therapeutics presented positive data from their phase 1 MAD study. The results indicated a good safety profile and good pharmacokinetic properties. Combining these results with previous results from the SAD study and its follow-up, Redeye raises its likelihood of approval.